**FOI Ref: 6319**

**Category(ies): Clinical - Drugs**

**Subject: Immune Thrombocytopenia (ITP)**

**Date Received: 01/04/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country. |
| 1. How many patients has your trust treated (for any disease) in the last 6 months (or the latest 6 months data you have available) with the following treatments:
* Revolade (eltrombopag)
* Nplate (romiplostim)
* Doptelet (avatrombopag)
* Tavlesse (fostamatinib)
 | 21700 |
| 1. In the last 6 months (or the latest 6 months data you have available), how many patients has your trust treated for immune thrombocytopenia (ITP)?
 | 29 |
| 1. Of the patients treated for immune thrombocytopenia (ITP) in the last 6 months (or the latest 6 months data you have available), how many were treated with:
* rituximab
* mycophenolate mofetil
* surgery (splenectomy)
 | Rituximab – 1Mycophenolate mofetil - 1Surgery (splenectomy) - Nil |
| 1. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?
 | No |